- Raymond Jamesupdated ProQR Therapeutics NV(NASDAQ: PRQR) to excel, based on the firm belief that "RNA editing" develops into a powerful therapeutic area in the coming years.
- Related:This penny stock biotech is shifting its eye portfolio to focus on RNA editing.
- The analyst notes that there are numerous targets, including alpha-1 antitrypsin deficiency, which Raymond James based the new model on (assume this…
Full story available at Benzinga.com
[ad_2]
Source story